Desiré Viola Trupia

Dr. Desiré Viola Trupia

orcid

Research Focus & Metrics

Representative Publications

View All Publications
20 July 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
SKShigeki Kusamura
Shigeki Kusamura
ABAdele Busico
Adele Busico
ECElena Conca
Elena Conca
ICIolanda Capone
Iolanda Capone
Luca AgnelliLuca Agnelli
Luca Agnelli
MDMarcello Deraco
Marcello Deraco
In pseudomyxoma peritonei (PMP), KRAS and GNAS mutations are frequent. We hypothesized that these mutations may contribute to the suppression of antitumor immunity: KRAS may induce GMCSF expression, while GNAS may enhance the expression of cyclic adenosine monophosphate and A2AR signaling. This study aimed to explore possible mechanisms facilitated by KRAS and GNAS mutations for escaping immune surveillance. Additionally, we looked for new potential therapeutic and prognostic targets in this rare disease which is poorly characterized at the molecular level. GM-CSF, A2AR, CD73, CD39, and PD-L1 expression was investigated by immunohistochemistry in 40 PMPs characterized for GNAS and KRAS mutational status. Immune cell populations were studied by immunohistochemistry and nanostring nCounter®. Following the criteria of a prognostic nomogram reported for PMP, we stratified the patients into two different risk groups, with 28 “low-risk” and 12 “high-risk” patients. We observed the expression of GM-CSF (74%); CD39 (37%); CD73 (53%); A2AR (74%); and PD-L1 (16%) which was unrelated to GNAS or KRAS status. The tumor microenvironment showed the presence of CD4+ T cells (86%); CD8+ T cells (27%); CD20+ B (67%); CD15+ cells (86%); and CD163+ M2 macrophages (67%), while CD56+ NK cells were absent. CD163 expression (27%) in PMP tumor cells was associated with poor prognosis. GNAS mutation and A2AR expression were not associated with a specific immune transcriptional signature. However, the expression assay revealed 21 genes associated with prognosis. The “high-risk” patients exhibited worse progression-free survival (HR = 2.3, CI 95%: 1.1–5.1, p = 0.034) and significant downregulation of MET, IL8, PPARG, DTX4, HMGA1, ZIC2, WNT5B, and CCRL2. In conclusion, we documented the presence of immunosuppressive factors such as GM-CSF, A2AR, and PD-L1 in PMP. These factors were not associated with GNAS and KRAS status and could be explored as therapeutic molecular targets. Additionally, a set of potential prognostic biomarkers, including CD163 expression in tumor cells, deserve further investigation.

8 July 2025 in Tumori Journal
Verified
Journal Article
Closed access
DLDaniele Lorenzini
Daniele Lorenzini
RSRebecca Salvatori
Rebecca Salvatori
CVChiara Costanza Volpi
Chiara Costanza Volpi
DTDesiré Viola Trupia
Desiré Viola Trupia
MNMonica Niger
Monica Niger
GPGiancarlo Pruneri
Giancarlo Pruneri
Introduction: Anti-HER2 drugs are becoming an important therapeutic option for various solid tumors, increasing the need for HER2 status testing. Comprehensive genomic profiling (CGP) panels, including FoundationOne®CDx, are commonly used to assess ERBB2 (encoding for HER2) copy number alterations. We aimed to evaluate the analytical validity of FoundationOne®CDx assay, by comparing ERBB2 copy number data with traditional HER2 status by immunohistochemistry (IHC)/in situ hybridization (ISH) assays in a heterogeneous cohort of solid tumor samples. Methods: We retrospectively reviewed the 531 cases evaluated by FoundationOne®CDx in our Institution, and HER2 status by IHC/ISH could be internally analyzed in 68 cases, including 31 (45.5%) gastroesophageal, 17 (25.0%) colorectal, four (5.8%) breast and two (2.9%) cholangiocarcinoma patients. Tumors with estimated ERBB2 copy number ⩾ 4 by FoundationOne®CDx, and tumors with strong and complete (3+) membranous staining by IHC and/or a HER2/CEP17 ratio ⩾2 by ISH were considered NGS positive and IHC/ISH positive, respectively. Results: We identified 21 NGS positive cases (30.9%); IHC/ISH analysis confirming overexpression/amplification in 16 cases (sensitivity: 76.2%), while among the 47 NGS negative cases, 45 were confirmed by IHC/ISH results (specificity: 90%), with a positive predictive value of 76.2% and a negative predictive value of 95.7%. Conclusions: FoundationOne®CDx provides an accurate evaluation of ERBB2 copy number status and may represent a cost-effective option in metastatic cancer patients for whom NGS testing is recommended.

30 April 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Annunziata GloghiniAnnunziata Gloghini
Annunziata Gloghini
DLDaniele Lorenzini
Daniele Lorenzini
CVChiara Costanza Volpi
Chiara Costanza Volpi
DTDesiré Viola Trupia
Desiré Viola Trupia
GPGiancarlo Pruneri
Giancarlo Pruneri
Classic Hodgkin lymphoma (cHL) is a distinctive B-cell malignancy defined by the presence of scarce but pathobiologically dominant Hodgkin Reed-Sternberg (HRS) cells within an inflammatory tumor microenvironment (TME). Although representing less than 10% of total tumor cellularity, HRS cells shape the TME by recruiting and functionally polarizing immune and stromal elements through cytokine- and chemokine-mediated signaling. Morphologically, HRS cells are large, atypical, often binucleated or multinucleated cells with prominent eosinophilic nucleoli and abundant cytoplasm, giving rise to the classic “owl’s eye” appearance. Distinct morphological variants—including lacunar, mummified, mononuclear, and anaplastic forms—contribute to the histopathologic diversity across cHL subtypes such as nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted disease. The immunophenotype of HRS cells is equally characteristic, with strong and uniform CD30 expression, frequent CD15 positivity, reduced expression of B-cell markers (CD20, CD79A/B), and partial retention of PAX5, reflecting profound lineage dysregulation. Aberrant expression of activation markers and immune-evasion molecules, including PD-L1 driven by recurrent 9p24.1 amplification, underscores their capacity for immune escape. Genetically, HRS cells display alterations affecting NF-κB, JAK/STAT, and PI3K/AKT pathways, facilitated by somatic mutations, chromosomal gains, and epigenetic remodeling that silence B-cell-defining genes. Despite reprogramming, clonality and somatic hypermutation patterns confirm their origin from germinal center B-cells, even in EBV-associated cases. Collectively, the morphology, phenotype, and genotype of HRS cells reveal a complex pathogenic network in which intrinsic oncogenic pathways and extrinsic TME interactions co-operate to sustain malignant transformation. Understanding these integrated mechanisms provides a biological foundation for current therapeutic strategies.

1 September 2025 in JCO Oncology Advances
Verified
Journal Article
Closed access
CCChiara Catania
Chiara Catania
DTDesiré Viola Trupia
Desiré Viola Trupia
CVChiara Costanza Volpi
Chiara Costanza Volpi
DLDaniele Lorenzini
Daniele Lorenzini
PBPaola Bossi
Paola Bossi
Tommaso De PasTommaso De Pas
Tommaso De Pas
PURPOSE: Tracheobronchial adenoid cystic carcinoma (TACC) is a rare malignancy arising from the submucosal glands of the trachea or main bronchi. Similar to its more common salivary gland counterpart (SG-ACC), TACCs display a strong propensity for local recurrence and distant metastases and current systemic treatment options are limited and often ineffective. Trophoblast cell surface antigen 2 (TROP-2) has emerged as a validated therapeutic target for antibody-drug conjugates (ADCs) and is highly expressed in SG-ACC. MATERIALS AND METHODS: We retrospectively analyzed 11 TACC specimens from the pathology archives of two Italian cancer reference centers. TROP-2 expression was assessed in all cases using immunohistochemistry. RESULTS: Immunohistochemistry for TROP-2 revealed positivity in all 11 specimens, with 10 showing high expression and one showing moderate expression. Three cases exhibited heterogeneous staining. CONCLUSION: These findings indicate a very high prevalence of robust TROP-2 expression in TACC. This provides a compelling rationale for the investigation of anti–TROP-2 ADCs, addressing a critical unmet need in this challenging rare thoracic malignancy.

14 August 2023 in Tumori Journal
Verified
Journal Article
Closed access
LSLaura Sala
Laura Sala
CCChiara Maura Ciniselli
Chiara Maura Ciniselli
FBFabio Bozzi
Fabio Bozzi
VSValeria Summo
Valeria Summo
CBChiara Bonini
Chiara Bonini
UCUmberto Cortinovis
Umberto Cortinovis
Introduction: The synthesis of the periprosthetic capsule during implant-based breast reconstruction is the result of a coordinate cascade of inflammatory events ending in a fibrous tissue deposition around the expander or implant. Although the development of small volumes of fluid is one of the complications of prosthetic-based breast reconstruction, the characterization of the periprosthetic effusions coupled with the micro-textured devices, that have been recently introduced after the recall of macro-textured ones, is still lacking. The investigation of these periprosthetic effusions and paired capsules in terms of immunological content were the primary and secondary aims of the present study, respectively. Methods: For this, 68 women, 41 of whom had periprosthetic effusions at the time of expander replacement with implant, were recruited. For each case, capsule and healthy dermal tissues were taken and for women with periprosthetic effusion, peripheral blood was also collected. Periprosthetic effusions and peripheral blood were characterized by cytometry while capsules and dermal tissues by immunohistochemistry and Nanostring analysis. Results: The results showed an increase of Th1, Th2 lymphocytes and a HLA-DR+bright CD16+ cells (likely representing monocytes-derived macrophages) in periprosthetic effusions in respect to peripheral blood. These pro-inflammatory cells were counterbalanced by the gain of suppressive CD4 Treg cells. In the corresponding capsules, immunohistochemistry revealed the absence of Th1 cells and the presence of tissutal FOXP3 Treg. No significant difference in expression of inflammatory-related genes between capsules and dermal tissues was present. Conclusions: These results suggest the presence of a Treg-controlled inflammation in both periprosthetic effusions and capsules.

19 March 2026 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
ABAlessia Bertolotti
Alessia Bertolotti
FBFabio Bozzi
Fabio Bozzi
ECElena Conca
Elena Conca
ADAndrea Devecchi
Andrea Devecchi
GDGianpaolo Dagrada
Gianpaolo Dagrada
AFAndrea Ferrari
Andrea Ferrari